clinical trial · NCT07677059
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Asthma (Diagnosis)KT-621
brief summary
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
started
Jun 25, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Oct 7, 2026
official title
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol